


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of ~~Compounds of the general~~ formula (I)



in which

R^1 represents phenyl or represents 5- or 6-membered heteroaryl having up to two heteroatoms from the group consisting of N, O and S, which radicals may for their part each be mono- to trisubstituted by identical or different substituents selected from the group consisting of halogen, cyano, nitro, (C₁-C₆)-alkyl (which for its part may be substituted by hydroxyl), (C₁-C₆)-alkoxy, trifluoromethyl, trifluoromethoxy, (C₁-C₆)-alkylsulphonyl, (C₁-C₆)-alkanoyl, (C₁-C₆)-alkoxycarbonyl, carboxyl, amino, (C₁-C₆)-acylamino, mono- and di-(C₁-C₆)-alkylamino,

R^2 and R^3 are identical or different and independently of one another represent hydrogen or (C₁-C₄)-alkyl or together with the carbon atom to which they are attached form a 3- to 7-membered spiro-linked cycloalkyl ring,

R^4 represents hydrogen or (C₁-C₄)-alkyl,

R⁵ represents hydrogen, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy or halogen,

R⁶ represents (C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl, (C₁-C₆)-alkanoyl, (C₁-C₆)-alkylsulphonyl or (C₁-C₆)-alkoxycarbonyl,

R⁷ and R⁸ are identical or different and independently of one another represent hydrogen or (C₁-C₄)-alkyl,

and

R⁹ represents hydrogen or a hydrolyzable group which can be degraded to the corresponding carboxylic acid,

or a ~~and their~~ pharmaceutically acceptable salt thereof ~~salts, solvates and solvates of the salts~~ .

2. (currently amended) The compound of ~~Compounds of the general formula (I) according to~~ Claim 1 in which

R¹ represents phenyl which may be mono- or disubstituted by identical or different substituents selected from the group consisting of fluorine, chlorine, cyano, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy, trifluoromethyl, trifluoromethoxy, methylsulphonyl, acetyl, propionyl, (C₁-C₄)-alkoxycarbonyl, amino, acetylamino, mono- and di-(C₁-C₄)-alkylamino,

R² and R³ are identical or different and independently of one another represent hydrogen or (C₁-C₄)-alkyl or together with the carbon atom to which they are attached form a 5- or 6-membered spiro-linked cycloalkyl ring,

R⁴ represents hydrogen or methyl,

R⁵ represents hydrogen, methyl, methoxy, fluorine or chlorine,

R⁶ represents (C₁-C₄)-alkyl, acetyl, methylsulphonyl, methoxycarbonyl or tert-butoxycarbonyl,

R⁷ and R⁸ are identical or different and independently of one another represent hydrogen or methyl,

and

R⁹ represents hydrogen.

3. (currently amended) The compound of ~~Compounds of the general formula (I)~~
according to Claim 1 in which

R¹ represents phenyl which may be mono- or disubstituted by identical or different substituents selected from the group consisting of fluorine, chlorine, methyl, trifluoromethyl and trifluoromethoxy,

R² represents methyl,

R³ represents methyl,

or

R² and R³ together with the carbon atom to which they are attached form a spiro-linked cyclopentane or cyclohexane ring,

R⁴ represents hydrogen or methyl,

R⁵ represents hydrogen, methyl, fluorine or chlorine,


R⁶ represents (C₁-C₄)-alkyl, acetyl or methylsulphonyl,

R⁷ and R⁸ each represent hydrogen

and

R^9 represents hydrogen.

4. (currently amended) A compound of ~~Compounds of the~~ formula (I-A)




in which

R^1 represents phenyl which is substituted by fluorine, chlorine or trifluoromethyl,

and

R^6 represents methyl, ethyl, n-propyl, isopropyl or tert-butyl.

5. (currently amended) A process ~~Process~~ for preparing a compound of claim 1 or 4,
comprising initially converting a compound ~~the compounds of the general formula (I) or~~
~~(I-A) as defined in Claims 1 to 4, characterized in that compounds~~ of the formula (II)




in which

R^2 , R^3 and R^4 are each as defined in Claim 1

and

Y represents chlorine or bromine

~~are initially~~ , by methods known from the literature, ~~converted~~ into a compound
~~compounds~~ of the formula (III)




in which

Y, R^2 , R^3 and R^4 are each as defined in Claim 1

and

PG represents a suitable amino protective group ~~, preferably 4-nitrophenylsulphonyl,~~
then reacting this compound ~~these compounds are then reacted~~ in a coupling
reaction with a compound of the formula (IV)




in which

R^1 is as defined in Claim 1

and

R^{10} represents hydrogen or methyl or both radicals together form a CH_2CH_2 - or $C(CH_3)_2-C(CH_3)_2$ -bridge


in an inert solvent in the presence of a suitable palladium catalyst and a base to give a compound ~~compounds~~ of the formula (V)



in which

PG, R^1 , R^2 , R^3 and R^4 are each as defined in Claim 1,


then again removing the protective group PG ~~is then~~, by methods known from the literature, ~~removed again~~ giving a compound ~~compounds~~ of the formula (VI)



in which

R^1 , R^2 , R^3 and R^4 are each as defined in Claim 1,

then converting the product ~~is then converted~~ with a compound of the formula (VII)




in which

R^5 , R^6 , R^7 and R^8 are each as defined in Claim 1

and

T represents benzyl or (C₁-C₆)-alkyl


in an inert solvent in the presence of a base into a compound ~~compounds~~ of the formula (VIII)



in which

T, R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 are each as defined in Claim 1,

then converting the compound ~~compounds~~ of the formula (VIII) ~~are then~~ , using acids or bases or, if T represents benzyl, also hydrogenolytically, ~~converted~~ into the corresponding carboxylic acid ~~acids~~ of the formula (IX)



in which

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 are each as defined in Claim 1,

then optionally further modifying this carboxylic acid (IX) ~~these carboxylic acids (IX) are, if appropriate, modified further~~ by known esterification methods to give a compound ~~compounds~~ of the formula (I),

and optionally converting the resulting compound ~~compounds~~ of the formula (IX) or (I) ~~are, if appropriate, converted~~ into a pharmaceutically acceptable salt thereof ~~their solvates, salts and/or solvates of the salts~~ using the corresponding (i) ~~solvents and/or (ii) bases or acids.~~

6. (cancelled)
7. (currently amended) A pharmaceutical composition ~~Medicaments~~, comprising at least one a compound of claim 1 or 4 ~~the formula (I) or (I-A) as defined in Claims 1 to 4~~ and an inert non-toxic pharmaceutically acceptable carrier ~~carriers, auxiliaries, solvents, vehicles, emulsifiers and/or dispersants~~ .
8. (cancelled)
9. (cancelled).
10. (currently amended) A method for treating or preventing ~~Use of compounds of the formula (I) or (I-A) as defined in Claims 1 to 4 for preparing medicaments for the~~

~~prophylaxis and treatment of stroke, arteriosclerosis, coronary heart diseases or and~~
~~dyslipidaemias , for the prophylaxis of myocardial infarction and for the treatment of~~
~~restenosis after coronary angioplasty or stenting , comprising administering to a patient a~~
therapeutically effective amount of a compound of claim 1 or 4 .

11. (cancelled)
12. (new) A method for preventing myocardial infarction, comprising administering to a patient a therapeutically effective amount of a compound of claim 1 or 4.
- 13 (new) A method for treating restenosis after coronary angioplasty or stenting, comprising administering to a patient a therapeutically effective amount of a compound of claim 1 or 4.